Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
Pooled result · Composite CV eventsResult — go to the resultHazard ratio 0.86 95% CI 0.78–0.95Authors' conclusion
Results of this subanalysis of the FIDELITY analysis suggest that CKD-associated composite cardiovascular risk may be modifiable with finerenone treatment in patients with T2D, those with eGFR of 25 or higher, and those with UACR of 30 mg/g or greater.
Study context
- Population
- Patients with T2D and chronic kidney disease (CKD)
- Participants
- 13,026 patients
- Comparison
- Finerenone vs placebo
- Outcome
- Composite CV events:
- CV death
- Nonfatal stroke
- Nonfatal MI
- Hospitalization for HF
- Follow-up
- Median 3.0 years
Methodological detailspooled analysis of 2 phase 3 trials, population-level simulation with NHANES data
- Pooled analysis of 2 phase 3 trials
- Population-level simulation with NHANES data
Pooled result
Composite CV events
Hazard ratio
0.86
95% CI 0.78–0.95
P = 0.002
Finerenonevs Placebo
HR 0.86 (95% CI 0.78–0.95); P = 0.002
As reported in the abstract
Further pooled results
per 100 patient-years
Placebo, UACR <300 mg/g
2.38 (95% CI 1.03–4.29) per 100 patient-years
Placebo, UACR ≥300 mg/g
3.78 (95% CI 2.91–4.75) per 100 patient-years
- Lower eGFR and higher albuminuria associated with higher CV event incidence
CV events incidence, Placebo, eGFR <30, by UACR · median 3.0 years
- Placebo, eGFR <30, UACR <300 mg/g: incidence per 100 patient-years
- 6.54 (95% CI 4.19-9.40)
- Placebo, eGFR <30, UACR ≥300 mg/g: incidence per 100 patient-years
- 8.74 (95% CI 6.78-10.93)
Simulated CV events prevented by 1 year of finerenone (population level)
- Treatment-eligible individuals
- 6.4 million (95% CI 5.4-7.4 million)
- CV events prevented
- 38 359 (95% CI 31 741-44 852)
- HF hospitalizations prevented
- ≈14 000
- Prevented in eGFR ≥60 (25 357 of 38 360)
- 66%
- Simulation with NHANES data
Original publication
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →